Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 pivotal trial of ARV 110 in the patients with AR T878/H875 tumor mutations

Next Previous
Search
Trial Profile

Phase 3 pivotal trial of ARV 110 in the patients with AR T878/H875 tumor mutations

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bavdegalutamide (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Arvinas

Most Recent Events

  • 08 Nov 2022 According to a Arvinas media release, Confirm final dose selection and secure final health authority feedback on trial protocol is expected in 1H 2023.
  • 04 Aug 2022 According to a Arvinas media release, the company plans to initiate a Phase 3 trial in metastatic castration-resistant prostate cancer, or mCRPC, for patients with AR T878/H875 tumor mutations in 2H 2023.
  • 28 Feb 2022 According to a Arvinas media release, this trial is expected to begin by year end-2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top